Initial treatment of COPD with LABA-ICS or LABA-LAMA: real-world comparative effectiveness
In a real-world clinical practice setting of COPD treatment, initiating therapy with LABA-ICS inhalers may be more effective than LABA-LAMA inhalers among patients with multiple exacerbations, particularly those with FEV<sub>1</sub>≥50% predicted, but less effective among those with no prior exacerbations and FEV<sub>1</sub><50% predicted. This study supports a targeted approach to initial therapy for COPD. .
Authors
- Pierre Ernst (ORCID: https://orcid.org/0000-0001-9983-3608)
- Samy Suissa (ORCID: https://orcid.org/0000-0002-1281-5296)
- Mathew Cherian (ORCID: https://orcid.org/0000-0001-5843-3886)
- Sophie Dell’Aniello (ORCID: https://orcid.org/0000-0002-4373-7876)
Institutions
- Jewish General Hospital (CA)
- McGill University (CA)
Publication Details
- Journal
- BMJ Open Respiratory Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/bmjresp-2025-003216
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00